Jincheng Pharm(SZ:300233)2022-12-07 08:32Company Overview - Shandong Jincheng Pharmaceutical Co., Ltd. has been actively pursuing a comprehensive development strategy in the pharmaceutical and healthcare sectors since its IPO, focusing on internal growth, external expansion, and mergers and acquisitions [3][4]. Business Development - The company has successfully completed the acquisition of Shanghai Tianchen Pharmaceutical in 2014 and is planning significant asset restructuring to invest in Beijing Langyi Pharmaceutical in 2015, along with additional investments in Guangzhou Jincheng Daobofa Pharmaceutical [3][4]. - As of now, the company has established a complete industrial chain from intermediates and raw materials to finished formulations, forming three major business systems: antibiotics, biopharmaceuticals, and gynecological and immune-regulating preparations [3][4]. Financial Performance - The company reported a significant growth of over 60% in the first three quarters of the year, primarily driven by the robust performance of the antibiotics segment, which contributes approximately two-thirds of the overall revenue [4][5]. - Domestic and foreign trade revenues are roughly equal, each accounting for about half of the total revenue [4][5]. Product Development - The intermediates business has shown steady growth, with major product sales increasing and prices rising compared to the same period last year, attributed to the company's leading market position and continuous innovation [4][5]. - The biopharmaceutical product glutathione has established business collaborations with major domestic formulation manufacturers and is exported to Europe, America, and Southeast Asia, despite facing some revenue pressure due to price adjustments [4][5]. Future Plans - The company is focused on enhancing its terminal formulation sales channels and has initiated the construction of a sales platform, with core sales personnel already in place [5][6]. - Following the acquisition of Beijing Langyi Pharmaceutical, the company aims to expand its product offerings in antibiotics, biopharmaceuticals, and gynecological and immune-regulating sectors, while also exploring strategic investments in liver disease treatment and other health sectors [6].